AGN 232411

Drug Profile

AGN 232411

Alternative Names: AGN232411

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 31 Mar 2016 Allergan completes a phase I trial in Healthy volunteers and in Dry eyes in USA (NCT02420730)
  • 01 Jun 2015 Phase-I clinical trials in Dry eyes in USA (Ophthalmic) (NCT02420730)
  • 22 Apr 2015 Allergan plans a phase I trial in Healthy volunteers and in Dry eyes in USA (NCT02420730)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top